The Resilient Response of Indian Companies during the Pandemic
Ashok Patel, Founder and CEO of Max Ventilator, reflects on the remarkable adaptability and innovation demonstrated by Indian companies in the face of the pandemic. He highlights how existing companies pivoted their operations and startups emerged with products that eased Covid management, including remote health monitoring devices, robotic systems, AI-based solutions, and disinfectants.
Nurturing an Indigenous R&D Ecosystem
Patel emphasizes the pivotal role of a robust indigenous R&D ecosystem in propelling India towards becoming a global leader in medical device manufacturing. He underscores the journey from conceptualizing ideas to designing, developing, and testing products, all of which can flourish within a thriving R&D environment.
Government’s Intent and Initiatives
Recognizing the significance of healthcare/medtech R&D, Patel acknowledges the government’s commitment to facilitating the growth of this sector. He cites the finance minister’s assurance of supportive policies, light-touch regulations, and collaboration among academia, industry, and public institutions. The Department of Pharmaceuticals‘ draft policy aimed at catalyzing research and innovation in the pharma-medtech sector is also highlighted.
R&D Challenges and the Path Forward
While acknowledging the capital-intensive and risky nature of R&D, Patel emphasizes the need for increased private investment in this domain. He calls for comprehensive policy support to attract more private players into healthcare/medtech R&D, ensuring that India’s innovation potential is fully realized.
Collaborative Partnerships for R&D Advancements
Patel highlights the importance of fostering collaborative partnerships between academia, industry, and public institutions to drive R&D advancements. He emphasizes that such partnerships can pool resources, expertise, and knowledge, leading to accelerated innovation and a more robust pipeline of cutting-edge products.
Encouraging Private Sector Participation
To further catalyze R&D growth, Patel suggests creating a conducive environment for private sector participation. He calls for the introduction of incentives such as tax breaks, grants, and research subsidies to attract private investments into healthcare/medtech R&D. By aligning financial benefits with innovative efforts, India can fuel a culture of exploration and discovery.
Empowering Startups for Innovation
Acknowledging the significant role of startups in driving innovation, Patel underscores the need to provide tailored support for emerging ventures. He suggests establishing innovation hubs, incubators, and accelerators dedicated to healthcare and medtech startups. These initiatives can offer mentorship, funding, and resources that nurture the growth of innovative ideas into impactful solutions.
Adopting Global Best Practices
Patel advocates for adopting international best practices in healthcare/medtech R&D to ensure global competitiveness. By benchmarking against global standards, Indian companies can enhance product quality, safety, and efficacy. This alignment with global norms not only boosts market acceptance but also elevates India’s reputation as a reliable and cutting-edge player in the medtech industry.
Empowering Regulatory Framework
A strong regulatory framework that balances innovation with safety is crucial for R&D success, Patel suggests. He highlights the importance of streamlined regulatory processes that expedite product approvals while maintaining rigorous quality standards. An efficient regulatory environment encourages companies to invest in R&D, confident that their innovations will navigate the approval process smoothly.
Long-term Vision for Sustainable Growth
Patel concludes by emphasizing the need for a comprehensive and long-term vision for R&D growth in Indian healthcare and medtech. He envisions a future where continuous investment, collaboration, and policy support drive sustained innovation, enabling India to lead the global medtech landscape and improve healthcare outcomes for all.